ADLM 2025, formerly known as AACC, is one of the world’s largest and most influential events in the field of laboratory medicine. It brings together thousands of professionals from clinical diagnostics, research, and industry. This year, attendees can explore more than 850 exhibitors presenting the latest technologies, services, and solutions across over 200 product categories — covering every aspect of the clinical laboratory and extending into molecular diagnostics, data analytics, and emerging healthcare technologies. ADLM 2025 offers a unique opportunity to discover innovation at every level of laboratory medicine and connect with global leaders in the field.
BioVendor Group brings together a portfolio of specialized technologies and diagnostic solutions that reflect the synergy of innovation, expertise, and flexibility across its companies. At ADLM 2025, we will present a broad range of tools supporting laboratories in the fields of immunodiagnostics and molecular diagnostics, covering everything from multiplex testing and CLIA assays to pharmacogenetics, microbiome profiling, and NGS-based oncology testing. Together, these solutions, developed by BioVendor Group companies, demonstrate our commitment to advancing personalized diagnostics.
START: 27 / 7 / 2025
END: 31 / 7 / 2025
McCormick Place, Chicago, IL
Booth #4255
More information: https://meeting.myadlm.org
Contact us: Barbora Vraná, vrana@biovendor.cz
TestLine is excited to present its latest developments in immunology and infectious disease diagnostics. The company will highlight its groundbreaking Microblot-Array (MBA) platform for effective multiplex diagnostics, as well as a fully automated CLIA solution featuring an attractive portfolio of parameters. TestLine aims to connect with new partners and make our unique solutions, more accessible to laboratories across the USA, Canada, and Latin America.
From DiaSource, the portfolio includes a wide range of clinical diagnostic RIA and ELISA products for endocrinology, autoimmunity, and infectious diseases. The company also supplies selected instrumentation for IVD laboratories worldwide and offers a collection of high-quality, internally developed antibodies with a special focus on their application in IVD assays. Its antibody and antigen portfolio covers 14 disease areas, including bone metabolism, diabetes, oncology, and Alzheimer’s disease.
The molecular diagnostics offering from ViennaLab will feature test kits and integrated analysis software across three product lines: RealFast™ Assays (Real-Time PCR), StripAssays® (PCR + Hybridization), and NGS Assays. Highlights include assays for HLA-B27 genotyping, pharmacogenetics (CYP2D6, DPYD), newborn screening (CF and CAH), and next-generation sequencing for gut microbiome profiling (bacteria and fungi), oncology, and clinical exome sequencing covering genes linked to rare diseases. These complete solutions streamline workflows from sample to result, making precision diagnostics faster, easier, and more accessible.
From BioVendor MDx, we will present cutting-edge NGS-based assays such as the fastGEN BCR::ABL1 Cancer Kit — the first commercial NGS assay for precise detection of the BCR::ABL1 fusion gene. It enables genotyping of kinase domain mutations and includes a dedicated bioinformatics solution. Another highlight will be the fastGEN MSI Kit for detecting microsatellite instability in tumor samples. It includes a bioinformatics analysis with a pre-set baseline derived from clinically stable samples, eliminating the need for matched normal tissue and streamlining the diagnostic process.
We’ll be happy to introduce these technologies and solutions in more detail at our booth. Stop by to get inspired, ask questions, and explore new opportunities for collaboration — we look forward to meeting you in Chicago!
Focusing on the latest trends and technologies in laboratory diagnostic
Read moreGet to know epicGEN – next-generation NGS panels for precise genome analysis. The new epicGEN Solid Cancer & MSI Kit is designed for targeted analysis of 42 genes relevant for the diagnostics of solid tumors and the detection of genetic changes (InDel, SNP, CNV and MSI).
Read moreBioVendor Group changes ownership to partner with a healthcare specialist, strengthening its development and expansion capacities in the global diagnostics market.
Read moreFrom sequencing to artificial intelligence: Trends shaping the future of laboratory diagnostics
Read moreWe’re excited to introduce our new GENOVESA website, designed to provide you with seamless access to advanced software solutions.
Read moreWhile this motto sets the tone for the upcoming MEDICA 2025, it perfectly encapsulated the spirit of this year’s event, which took place in the second week of November in Düsseldorf.
Read moreBioVendor Group introduces the innovative test for the detection of microsatellite instability leverages state-of-the-art NGS technology
Read moreReveal lactose, fructose, and histamine intolerance with NGS – all in one test.
Read moreCutting-edge immunological biomarker and its role in managing infections and immune responses
Read moreThe 57th ESHG 2024 is behind us, gathering over 4,500 experts in human genetics.
Read moreBioVendor MDx introduces the first commercial NGS assay for the detection of the BCR::ABL1 fusion gene.
Read moreThe BioVendor Group CLIA project is in its third year of operation on the market and is successfully establishing itself in prestigious workplaces in the Czech Republic and other markets.
Read moreFirst impressions of Medlab 2024
Read moreTogether under one roof of BioVendor Group again after one year in Düsseldorf.
Read moreThe ECCMID conference showcased the latest findings in clinical microbiology and infectious diseases. And BioVendor Group was part of it!
Read moreA major advance in personalized medicine.
Read moreThese were the words of Michal Šteffl, Head of International Sales at TestLine, who summed up the participation of BioVendor Group companies at the most important event in the MENA region.
Read moreWe introduce to you our comprehensive and fast solution for the analysis of the CFTR gene.
Read moreIt is an annual occasion to meet our current business partners and suppliers and make new connections.
Read moreWe introduced a new tool for effective endometrial tumor analysis at the Mendel genetics conference.
Read moreBioVendor Group establishes the molecular diagnostic division BioVendor MDx.
Read moreThe most important medical fair took place in its usual autumn term from 15 to 18 November 2021 in Düsseldorf, Germany.
Read moreBioVendor developed user friendly diagnostic NGS kits with excellent analytical parameters and extremely fast processing for laboratories of any size.
Read moreBioVendor Group becomes the exclusive distributor of innovative tests to detect testicular cancer.
Read moreIntroducing the CLIA solution from BioVendor Group – an attractive portfolio of parameters, finely-tuned automation, new diagnostic possibilities.
Read moreThe prestigious Medlab Middle East 2021 show took place in Dubai from 21st to 24th June, and we couldn't miss it.
Read moreFully automated CLIA solution with diagnostic parameters from BioVendor Group
Read moreIntroducing the new BioVendor Group identity!
Read more
TEAMS internet platform
BioVendor is a proud member of strong academic-industrial consortium focused on research and development in the field of non-coding RNA diagnostics in oncology!
Read moreBioVendor is a proud member of a unique research cluster for the treatment of stroke
Read moreWe have established a new product segment within the BioVendor portfolio covering covid-19 relevant products.
Read moreWe continue to manufacture and supply in an unchanged manner!
Read moreBioVendor was a part of the largest attended laboratory expo worldwide.
Read moreNow we are getting closer to our goal - translating miRNA biomarkers from research to clinical diagnostics!
Read moreA succesful exhibition at MEDICA attracted many visitors and business partners.
Read moreBioVendor researchers evaluate “Clinical Utility of Current microRNA Detection Methods” in a BioTechniques journal article.
Read moreWe are pleased to announce that we have successfully participated in the External Quality Assessment (Referenzinstitut für Bioanalytik, survey of March 2019), being involved in determination of IL-6.
Read moreWe are so proud that BioVendor's ANGPTL3 Human ELISA participated in a major study.
Read moreGreat pleasure! We thank all who attended BioVendor seminar where MiRXES introduced GASTROClear, a diagnostic microRNA panel for Gastric cancer screening.
Read moreWe are pleased to announce that we have successfully participated in the External Quality Assessment (INSTAND, survey of March 20, 2019), being involved in determination of Cystatin C.
Read moreWe would like to invite you to a one-day expert seminar organized in cooperation with MiRXES on May 13, 2019.
Read moreBioVendor held distributor meeting in Brno with tour the laboratories and visiting unique Mendel Museum & Augustinian Abbey in Brno.
Read moreGreat to see everyone at 9th Gene Quantification Event in Freising-Weihenstephan.
Read moreBioVendor was a part of the largest attended laboratory expo worldwide.
Read more3rd Annual distributor meeting of BioVendor Group was in a new format this year.
Read moreA succesful exhibition at MEDICA attracted many visitors and business partners.
Read moreBioVendor was a part of the AACC congress in Chicago, USA.
Read moreWe will introduce BioVendor original miREIA method for microRNA quantification at the Harvard Medical School soon.
Read moreWithin the framework of our continous expansion of IVD products, we are happy to announce that further BioVendor products are now available for IVD use.
Read moreBioVendor was a part of the European Atherosclerosis Society (EAS) congress in Lisbon, Portugal.
Read moreBioVendor was a part of the largest attended laboratory expo worldwide
Read moreA succesful exhibition at MEDICA attracted many visitors and business partners
Read moreWe are proud to announce launch of the first miREIA kit.
Read moremiREIA Presented at the AACC 2017, San Diego
Read more